1. Home
  2. AVDL vs XERS Comparison

AVDL vs XERS Comparison

Compare AVDL & XERS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • AVDL
  • XERS
  • Stock Information
  • Founded
  • AVDL 2015
  • XERS 2005
  • Country
  • AVDL Ireland
  • XERS United States
  • Employees
  • AVDL N/A
  • XERS N/A
  • Industry
  • AVDL Biotechnology: Pharmaceutical Preparations
  • XERS Biotechnology: Pharmaceutical Preparations
  • Sector
  • AVDL Health Care
  • XERS Health Care
  • Exchange
  • AVDL Nasdaq
  • XERS Nasdaq
  • Market Cap
  • AVDL 1.5B
  • XERS 1.3B
  • IPO Year
  • AVDL 1996
  • XERS 2018
  • Fundamental
  • Price
  • AVDL $14.35
  • XERS $8.33
  • Analyst Decision
  • AVDL Strong Buy
  • XERS Strong Buy
  • Analyst Count
  • AVDL 8
  • XERS 7
  • Target Price
  • AVDL $20.88
  • XERS $8.00
  • AVG Volume (30 Days)
  • AVDL 1.3M
  • XERS 2.1M
  • Earning Date
  • AVDL 11-11-2025
  • XERS 11-07-2025
  • Dividend Yield
  • AVDL N/A
  • XERS N/A
  • EPS Growth
  • AVDL N/A
  • XERS N/A
  • EPS
  • AVDL N/A
  • XERS N/A
  • Revenue
  • AVDL $221,075,000.00
  • XERS $246,025,000.00
  • Revenue This Year
  • AVDL $64.56
  • XERS $43.89
  • Revenue Next Year
  • AVDL $30.60
  • XERS $20.40
  • P/E Ratio
  • AVDL N/A
  • XERS N/A
  • Revenue Growth
  • AVDL 132.35
  • XERS 35.62
  • 52 Week Low
  • AVDL $6.38
  • XERS $2.73
  • 52 Week High
  • AVDL $16.66
  • XERS $8.51
  • Technical
  • Relative Strength Index (RSI)
  • AVDL 43.90
  • XERS 61.63
  • Support Level
  • AVDL $14.85
  • XERS $7.88
  • Resistance Level
  • AVDL $15.58
  • XERS $8.51
  • Average True Range (ATR)
  • AVDL 0.48
  • XERS 0.37
  • MACD
  • AVDL -0.26
  • XERS -0.01
  • Stochastic Oscillator
  • AVDL 12.16
  • XERS 83.05

About AVDL Avadel Pharmaceuticals plc

Avadel Pharmaceuticals PLC is a specialty pharmaceutical company. The group focused on transforming medicines to transform lives. It provides solutions to the development of medications that address the challenges patients face with current treatment options. The company is engaged in the development of differentiated drug products for administration in various forms such as capsules, tablets, injectables etc. Its commercialized product LUMRYZ is an extended-release formulation of sodium oxybate indicated to be taken once at bedtime for the treatment of cataplexy or EDS in adults with narcolepsy. It operates in one segment, the development and commercialization of pharmaceutical products, including controlled-release therapeutic products based on its proprietary polymer-based technology.

About XERS Xeris Biopharma Holdings Inc.

Xeris Biopharma Holdings Inc is a biopharmaceutical company focused on developing and commercializing therapies for people with chronic endocrine and neurological diseases in the United States. It offer Recorlev for the treatment of Cushing's syndrome, Gvoke for the treatment of severe hypoglycemia, and Keveyis for the treatment of Primary Periodic Paralysis (PPP).

Share on Social Networks: